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Summary. Prevention of exposure to Plasmodium falciparum infection during infancy 










protection from clinical malaria was associated with balanced pro-inflammatory and 














Background. The effect of timing of exposure to first Plasmodium falciparum infections 
during early childhood on the induction of innate and adaptive cytokine responses and their 
contribution to the development of clinical malaria immunity is not well established.  
Methods. As part of a double-blind randomized placebo-controlled trial in Mozambique using 
monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively 
control timing of malaria exposure during infancy, peripheral blood mononuclear cells 
collected at ages 2.5, 5.5, 10.5, 15 and 24 months were stimulated ex vivo with parasite 
schizont and erythrocyte lysates. Cytokine mRNA expressed in cell pellets and proteins 
secreted in supernatants were quantified by real time quantitative PCR and multiplex flow 
cytometry, respectively. Children were followed up for clinical malaria from birth until 4 years 
of age.  
Results. Higher pro-inflammatory (IL-1, IL-6, TNF) and regulatory (IL-10) cytokine 
concentrations during the second year of life were associated with reduced incidence of 
clinical malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria 
exposure. Significantly lower concentrations of antigen-specific TH1 (IL-2, IL-12, IFN-) and 
TH2 (IL-4, IL-5) cytokines by 2 years of age were measured in children under 
chemoprophylaxis compared to children receiving placebo (p<0.03). 
Conclusions. Selective chemoprophylaxis altering early natural exposure to malaria blood 
stage antigens during infancy had a significant effect on TH lymphocyte cytokine production 
more than one year later. Importantly, a balanced pro-inflammatory and anti-inflammatory 
cytokine signature probably by innate cells around age 2 years was associated with 






















In endemic areas, clinical malaria primarily affects children under the age of 5 years [1]. 
Exposure to repeated Plasmodium falciparum infections from birth leads to the development 
of naturally acquired immunity, which is attained faster against the most severe forms of 
malaria, takes longer against milder forms but is never sterilizing [2]. Young children exposed 
to P. falciparum are at high risk from suffering malaria complications until they have 
developed partial clinical immunity, but the immune mechanisms involved and their 
determinants are not fully elucidated. Specifically, cellular immune correlates of protection 
against P. falciparum have been less characterized [3] in contrast to antibodies that are 
known to exert an anti-parasitic effect [4].  
Cytokines and chemokines mediate cellular immune responses and contribute in part to 
some of the symptoms and pathological alterations during malarial disease [5]. The outcome 
of the infection depends on the regulation of a network of pro-inflammatory and regulatory 
immune responses, leading to protection or immunopathology [6, 7]. There are little field data 
available on the relevance of individual cytokines or chemokines in acquired immunity to 
malaria. To date, the factors shown to be potentially implicated in protective immunity include 
IFN-γ and TNF produced by T cells that may inhibit parasite development and destroy 
infected hepatocytes [8, 9]; IFN-γ and memory T cells that activate macrophages to 
phagocyte parasitized erythrocytes and merozoites [10]; and IL-10 produced by regulatory T 
lymphocytes and other cells that control pathogenesis [11]. Antigen-specific TH1 responses 
are clearly involved in protection against malaria in animal models [12], but human data are 
scarcer. IL-12, a key TH1 cytokine produced mainly by antigen presenting cells, induces and 
regulates dendritic cell maturation and function, in addition to promoting the activation and 
IFN-γ production of T cells and natural killer (NK) cells [13]. IFN-γ and IL-2 TH cell responses, 
as well as γδ T cells, are induced after P. falciparum experimental infection in naïve 
individuals; IFN-γ has been associated with malaria protection [14] and IL-2 may be key for 










signatures correlate with immunity, it is not clear if they reflect innate rather than protective 
adaptive immune responses, particularly in the immature immune system of a child [16]. Re-
exposure to P. falciparum has been associated with acquisition of antigen-specific IL-10 
immunoregulatory responses that dampen pathogenic inflammation while enhancing anti-
parasite effector mechanisms [11, 17]. 
Most previous studies of cytokine responses and malaria immunity have been done in 
newborn cord blood samples [18, 19], in adult populations [20] or in cross-sectional studies 
after the onset of clinical symptoms [21-23]. Few have investigated the early acquisition of P. 
falciparum-specific cytokine responses in asymptomatic or healthy young infants and their 
relationship with development of clinical immunity in prospective cohorts [7, 9, 11, 24, 25] or 
how they are affected by malaria chemoprevention or therapeutic tools [26, 27]. Data 
reported have not shown consistent patterns. For example, in Gambian children, 
chemoprophylaxis resulted in higher lymphoproliferative responses and IFN-γ production 
[28]. In Ugandan children, chemoprophylaxis was associated with higher production of IL-2 
and TNF, which was associated with malaria protection, and lower production of IL-10 and 
IFN-γ, which was associated with malaria risk [27]. Also, Kenyan children sleeping under 
bednets had decreased production of pro-inflammatory cytokines TNF, IL-1 and IL-6 [29].  
We conducted a double-blind randomized placebo-controlled trial in Mozambique 
administering monthly chemoprophylaxis with sulfadoxine-pyrimethamine (SP) plus 
artesunate (AS) to selectively control the age of first infection by blood stage P. falciparum 
during infancy, to understand the role of parasite exposure in the acquisition of immunity to 
malaria [30]. This study set out to elucidate the role of age and exposure to P. falciparum in 
the induction of cytokine responses and their role in immunity in young children. To this end, 
we measured cellular mediators produced by blood leukocytes after parasite antigen or mock 










MATERIALS AND METHODS 
Study design 
The study was conducted at the Centro de Investigação em Saúde de Manhiça (CISM), 
Maputo Province, Southern Mozambique, from September 2005 to March 2009, and has 
been described in detail elsewhere [30]. Briefly, it consisted on a double-blind randomized 
placebo-controlled trial (RCT) including 349 newborns from the Maragra village receiving 
monthly chemoprophylaxis with SP plus AS or placebo administered during different periods 
of the first year of life according to the randomization group (Supplementary methods and 
Figure 1): “Late Exposure”, “Early Exposure” or “Control”. Study participants were followed 
up until age 24 months as part of the RCT. Weekly active case detection (ACD) was 
conducted from birth to approximately age 10.5 months and monthly home visits from 10.5 to 
24 months of age. Children presenting fever were taken to the Maragra Health Post (MHP), 
where they were examined and parasitaemia and hematocrit were determined. Additionally, 
passive case detection (PCD) was carried out at the MHP and Manhiça District Hospital 
(MDH) through the continuous morbidity surveillance system to monitor attendances to the 
outpatient clinics and admissions to hospital; data were analyzed until children were 4 years 
of age. One mL blood sample was collected into EDTA microtainers by finger-prick at the five 
cross-sectional visits by months [M] 2.5, 5.5, 10.5, 15 and 24, at the first clinical malaria 
episode (if any) and one month later (convalescence). Approval for the study was obtained 
from the National ethical review committee of Mozambique and the ethical review committee 
of Hospital Clínic in Barcelona, Spain. Children were enrolled in the study after their 
guardians provided written informed consent. 
 
Laboratory procedures 
Standard laboratory methods were used to assess parasitological and hematological 










Lymphoprep gradient and resuspended in complete medium. A total of 1.2 million fresh 
PBMC were stimulated with 20 μl of a P. falciparum (3D7 strain) schizont extract 
corresponding to lysate from 2 million synchronized infected red blood cells (iRBC) or with 20 
μl of uninfected RBC (uRBC). After the incubation for 24 h, 48 h or 72 h, the supernatants 
were collected and frozen at -80ºC. The PBMC pellets were collected in trizol and frozen at -
80ºC. At the end of the field study, supernatants were thawed and cytokine concentrations 
(IL-12p70, IFN-, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, IL-1, TNF, TNF-) were measured with 
the Bender MedSystems Human Th1/Th2 11plex FlowCytomix Multiplex Kit [32]. Cytokine 
mRNA levels (IL-2, IL-4, IL-6, IL-10, IFN-, TNF, IL-13) normalized to the reference gene 
RPL13a, were measured in a sub-sample by reverse transcriptase (RT) qPCR. A high level 
of cytokine production detected in culture supernatants of unstimulated infant samples are 
considered biologically relevant and were therefore not subtracted from the stimulated 
samples but shown side by side [19, 33]. Cytokine concentrations were analyzed in relation 
to plasma antibody responses to P. falciparum blood stage antigens [34]. 
 
Definitions and statistical methods 
Clinical malaria was defined as axillary temperature ≥ 37.5 ºC or a reported fever in the 
preceding 24 h with any positive parasitaemia from the blood slide microscopy, using a case 
definition previously validated in the area for this age group [35]. Cytokine concentrations 
(pg/mL) were logarithmically transformed and average within the groups presented as 
geometric means (GM) plus 95% confidence intervals (CI). Differences among treatment 
groups at different timepoints were estimated by ANOVA and evaluated using a likelihood 
ratio test and a global p-value for significance. Correlations with antibody levels within and 
between visits were done by Spearman. To analyze factors independently associated with 
cytokine concentrations we used mixed-effects regression models including relevant 










negative binomial regressions, unadjusted and after adjusting by relevant covariates. Data 
analysis was performed using STATA 11 (StataCorp. 2007) and R studio. Statistical 
significance was defined at P<0.05. 
 
RESULTS 
A total of 1,712 blood samples were collected from children and processed during the field 
study: 318 at M2.5, 295 at M5.5, 290 at M10.5, 273 at M15, 301 at M24, 129 at first acute 
malaria episode, and 106 at convalescence. Data presented here are based on the analysis 
of a random subgroup of 643 sets of supernatants (iRBC and uRBC stimulated, M2.5=93, 
M5.5=95, M10.5=220, M15=89, M24=35, 59 acute and 52 convalescent). In addition, 316 
sets of cell pellets in Trizol (iRBC and uRBC stimulated, 632 total) were processed for mRNA 
cytokine analysis (M2.5=59, M5.5=60, M10.5=192, M15=59, M24=11, 10 acute and 9 
convalescent). A pilot study was conducted to select the optimal timepoint among 24, 48 and 
72 h for cytokine detection in supernatants and in Trizol pellets after PBMC stimulation with 
iRBC using samples from 24 immune adults and 28 infants. Data indicated that the 24 h 
timepoint was the optimal for cytokine detection [19]. The correlations between mRNA 
expression in PBMC pellets and concentration in culture supernatants for quantifiable 
cytokines were moderate-high for IL-6, TNF and IL-10 that had the highest production but 
low for the others (Supplementary Figure 2).  
 
Factors affecting cytokine concentrations 
SP+AS chemoprophylaxis during M2.5-M5.5 or M5.5-M10.5 significantly affected the 
production of TH1 and TH2 cytokines in PBMC collected at M24 following iRBC antigen 
stimulation but not upon uRBC mock stimulation. Thus, children who had been chemo 
suppressed in year one had significantly lower supernatant concentrations of IL-12 (p=0.01), 










continuously exposed controls (Figure 1). Chemoprophylaxis had no significant impact on the 
pro-inflammatory (IL-1, IL-6, TNF, TNF-, IL-8) or the regulatory (IL-10) cytokine 
concentrations (Table 1).  
Clinical malaria episodes significantly affected the magnitude of some cytokine responses. 
Overall, pro-inflammatory cytokines and IL-10 were higher during the acute phase compared 
to levels preceding clinical disease and declined at convalescence. Differences were 
significant for the secreted proteins and mRNA transcripts (Table 2). 
Other factors evaluated in relation to cytokine production (maternal infection, parity, season, 
birth weight, etc) did not show any specific or consistent association, except for weight-for-
age Z-score that was negatively associated with levels of pro- and anti-inflammatory 
cytokines (Supplementary Table 1). Exposure to previous or current P. falciparum infection 
was not associated with cytokine concentrations. Age significantly affected the production of 
some cytokines during the first year of life. IL-6 levels were higher at M2.5 and declined 
gradually (Figure 1). IL-2 and IL-8 showed a steady increase with age, whereas IL-1 and 
TNF did not vary during most of the first year.  
 
Effect of cytokine concentrations on clinical malaria 
Higher concentrations of pro-inflammatory cytokines in PBMC supernatants by the end of the 
first year of life were associated with reduced incidence of clinical malaria up to M24. Table 3 
shows the effect of a 2-fold increment in cytokine levels at M10.5 on the incidence of malaria 
up to M24, adjusted by treatment, season, neighborhood, malaria infection at visit and before 
visit, maternal infection, congenital infection, inflammation in the placenta, use of insecticide 
treated nets (ITN) and indoor residual spraying (IRS). This was statistically significant for 
TNF and a trend was observed for IL-1, IL-6 and IL-8. Furthermore, as part of an extended 
follow up analysis (Supplementary Figure 1), higher secretion of pro-inflammatory and also 










falciparum antigen stimulation, was associated with lower risk of subsequent clinical malaria 
up to M36 and M48 (Table 3). 
 
Correlations among cytokine and antibody responses 
Different patterns were observed at each visit. Pro- and anti-inflammatory cytokines were 
highly and positively correlated from the younger ages, except for IL-8 that was negatively 
correlated to the rest, while TH1 and TH2 cytokines correlated positively among themselves 
only as age increased (Supplementary Figure 3). With time, weak-moderate correlations of 
inflammatory with TH cytokines transitioned from negative to positive. In addition, TNF and IL-
6 at M10.5 weakly correlated positively with TH2 cytokines at M24 (Supplementary Figure 4). 
We tested associations of cytokines affected by chemoprophylaxis or involved in malaria 
protection with antibody responses [34]. At M24, TH cytokines correlated positively with M5.5 
IgM to P. falciparum lysate, and negatively with M5.5 IgG to MSP1 and EBA175, M10.5 IgG 
to VSA, and various anti-malarial antibodies at M15 (Supplementary Figure 5A-B) and M24, 
particularly IgG to VSA and EBA175 (Figure 2A).  
Regarding inflammation cytokines, TNF, IL-1, IL-6 and IL-10 at M10.5 correlated negatively 
with IL-8 and IgM to malarial antigens at M5.5 (Supplementary Figure 5C). TNF correlated 
positively with M10.5 iRBC IgM while IL-6 correlated negatively with iRBC IgG 
(Supplementary Figure 5D). At M24, IL-10 correlated negatively with M10.5 AMA1 IgG; TNF, 
IL-1, IL-6 and IL-10 correlated negatively with M15 iRBC antibodies (Supplementary Figure 
5E-F), and M24 AMA1 and MSP1 IgMs (Figure 2B), while they correlated positively with M15 











This study shows that a pro-inflammatory (IL-1, IL-6, TNF) and regulatory (IL-10) cytokine 
signature between 1 and 2 years of age is associated with less incidence of malaria up to 
ages 3 and 4 years, having adjusted by chemoprophylaxis and prior malaria exposure. In 
terms of what responses correlate with timing of first infection in infancy, children receiving 3- 
to 5-month malaria chemoprophylaxis in the first year of life (early and late exposure groups) 
had significantly lower concentrations of antigen-specific TH1 (IL-2, IL-12 and IFN-) and TH2 
(IL-4, IL-5) cytokines at 2 years of age compared to children under continuous P. falciparum 
exposure. Since our analysis was done in a RCT with longitudinal design [30], selectively 
controlling by monthly chemoprophylaxis exposure to blood stage P. falciparum, results can 
more reliably shed light into the determinants of the acquisition of cellular immune responses 
in early childhood. However, the two subsets of cytokines were non-overlapping and thus we 
found no evidence that altering the timing of initial P. falciparum exposure impacts 
subsequent development of clinical immunity, consistent with the main trial results [30]. 
Remarkably, a chemoprophylactic intervention altering natural exposure to P. falciparum 
blood stages in infancy had an effect on the T cell adaptive response that was apparent over 
1 year later. Lower TH cytokine concentrations at M24 correlated with higher anti-P. 
falciparum IgG levels at M24 and prior visits, and lower anti-P. falciparum IgM levels at M5.5, 
indicating that antibodies could be markers of exposure in children who received prophylaxis 
in year 1. Indeed, in the RCT, early and late exposure groups had lower incidence of malaria 
in year 1 but higher in year 2 than the control group [30]; although a potential malaria 
“rebound” in year 2 was not statistically significant, this could be reflected immunologically. 
Thus, higher malaria exposure between M10.5-M24 as a result of chemoprophylaxis 
between M2.5-10.5 could have dampened the production of TH cytokines at M24. 
Higher concentrations of inflammatory cytokines at M10.5 and M24, associated here with 










indicative of less recent/current exposure, at prior timepoint visits. The fact that the 
association between pro-inflammatory cytokines and protection was observed in iRBC- and 
uRBC-stimulated PBMC suggests that these responses were produced by innate rather than 
adaptive cells [36, 37]. In contrast, the TH signature at M24 was only detected in iRBC-
stimulated PBMC, suggesting that these cytokines were produced by memory T cells. Infants 
recruited were initially naïve, and the non-specific innate immune response has been 
reported as the key defense mechanism in this population [38, 39]. TNF has correlated with 
immunity to clinical malaria in children [9], while IL-1 and IL-6 in the mothers from this cohort 
were also associated with less malaria [19].  
Furthermore, the pro-inflammatory protective signature was accompanied by a regulatory 
protective IL-10 response at age 2 years, when TNF levels diminished, showing that effective 
immunity against clinical malaria requires a pro-inflammatory followed by an anti-
inflammatory response. In previous studies, IL-10 was elevated as a result of poor immune 
regulatory ability typically seen in children, and as a result of the absence of acquired 
immunity due to a lack of previous exposure to malaria [22]. During acute malaria, pro-
inflammatory and TH1 cytokines had higher concentrations, which were more significant for 
IFN-, TNF and IL-10. IFN- is produced by NK cells, -T cells, CD8+ and CD4+ T cells, 
therefore it is both an innate and adaptive cytokine. Increased IFN- during acute malaria is 
related to protection against malaria [8, 9, 14]. The fact that regulatory IL-10 was higher 
during acute phase and declined at convalescence further supports that regulatory balanced 
responses are acquired in adequate immunity to control excessive inflammation [11]. 
In contrast with antibody responses [34], age or prior/present infection had no prominent 
influence on the magnitude of the cytokine response, consistent with previous studies by our 
group [26]. Cytokine concentrations except IL-2 and IL-8 declined by M24. At the age of 2 
years, when the spleen matures and the incidence of severe malaria declines [2], there 
appears to be an inflexion point in the acquisition of immunity. Indeed, key responses for 










associated with malaria protection in children from the same area [40]. A limitation of our 
study is that it was not designed to assess cytokines after M24, at a time when a protective 
adaptive TH signature correlated with immunity could have emerged. Another limitation is that 
we did not phenotype the cells producing the cytokines. Also, a larger sample size could 
have established more statistically conclusive associations between TH and inflammatory 
cytokines, and malaria. 
Finally, this study could portray, in a small scale, the impact of drug usage during malaria 
elimination programs including partial or temporary interruption of exposure by artemisinin-
based combination therapies, on acquisition of protective immunity to malaria. Suppressive 
doses of SP+AS during a defined period prevented infection and altered development of 
natural immunity but not completely. It remains to be assessed how quickly sustained 
chemoprophylaxis or mass drug administration would slow down or interrupt acquisition of 
immunity and/or could cause a loss of immunity at a population level [41]. 
 
Conclusions 
A balanced pro-inflammatory and anti-inflammatory cytokine response at age 2 years may be 
required for the acquisition of protective clinical immunity to malaria in childhood. In addition, 
timing of malarial antigen immune priming in infancy did not impact development of clinical 
immunity within the first 2 years but it may affect the subsequent acquisition of adaptive T 
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Figure 1. Weighted scattered plots of Plasmodium falciparum antigen-specific cytokine 
concentrations (pg/mL) in each study group and at each cross sectional visit, showing 
geometric means and 95% confidence intervals. A) TH1: IL-12, IL-2, IFN-B) TH2: IL-4, IL-5. 
C) Pro-inflammatory and regulatory: IL-1, IL-6, TNF, IL-8 and IL-10. Table 1 shows the 
outcomes of the statistical tests for the comparisons that had significantly different cytokine 
responses. The area of the symbol is proportional to the number of observations; in red 
those with previous or current P. falciparum infections. In the case of TH1 and TH2 cytokines 
at cross sectional visit 24 months, most concentration values were low or undetectable for 
the LE and EE groups (i.e. larger area of red and blue symbols at the bottom). Ctrol: control, 
LE: late exposure, EE: early exposure. 
 
Figure 2. Heatmaps and scatter plots of the correlations between antibody levels and 
cytokine concentrations after stimulation with P. falciparum schizont lysate (log-transformed) 
at the indicated study visits. A) Antibodies vs TH1 and TH2 cytokines at month 24. B) 
Antibodies vs pro-inflammatory and regulatory cytokines at month 24. Spearman coefficients 












Table 1. Effect of chemoprophylaxis on the magnitude of cytokine production at cross-
sectional visits. A) Heatmap of all cytokines, statistically significant differences in grey, non-
significant differences in white. B) Statistically significant proportional differences (95% 
confidence intervals) in chemoprophylaxis groups compared to control group in the case of 
TH1 and TH2 cytokines at month 24. 
A) 
  
Months 2.5 5.5 10.5 15 24 
TH1 cytokines 
IL-12 iRBC           
  uRBC           
IL-2 iRBC           
  uRBC           
IFN- iRBC           
  uRBC           
TH2 cytokines 
IL-4 iRBC           
  uRBC           
IL-5 iRBC           
  uRBC           
Pro-inflammatory 
cytokines 
IL-1β iRBC           
  uRBC           
IL-6 iRBC           
  uRBC           
TNF iRBC      










TNF- iRBC           
  uRBC           
Regulatory 
cytokines 
IL-10 iRBC           
  uRBC           
Pro-inflammatory 
chemokine 
IL-8 iRBC           





BB)   Proportional difference (95% CI) vs Control 
 
   Late exposure Early exposure p value 
TH1 IL-12 iRBC 0.25 (0.08-0.75) 0.29 (0.10-0.83) 0.0178 
   uRBC     ns 
 IL-2 iRBC 0.35 (0.15-0.84) 0.45 (0.20-1.01) 0.0337 
   uRBC     ns 
 IFN- iRBC 0.20 (0.06-0.66) 0.15 (0.05, 0.47) 0.0024 
   uRBC     ns 
TH2 IL-4 iRBC 0.35 (0.16-0.77) 0.33 (0.16-0.70) 0.0055 
   uRBC     ns 










   uRBC     ns 
p-value from linear regression model using Likelihood Ratio Test. ns = non-significant  










Table 2. Effect of a clinical malaria episode on the magnitude of cytokine production after 
stimulation with Plasmodium falciparum lysate at the acute and convalescent visits. P-values 
from regression models using Likelihood Ratio Test. Only significant differences are shown. 





95% CI P 
IFN Pre-Acute 40 1.77 1  -  
0.0022 secreted Acute 59 4.05 2.25 (1.19, 4.28) 
 Convalescent 51 1.46 0.81 (0.42, 1.57) 
IL-2 Pre-Acute 52 13.98 1  -  
0.0117 secreted Acute 59 10.05 0.72 (0.57, 0.91) 
 Convalescent 52 10.22 0.73 (0.57, 0.93) 
IL-4 Pre-Acute 52 15.43 1  -  
0.0240 secreted Acute 59 12.69 0.82 (0.66, 1.02) 
 Convalescent 52 11.22 0.72 (0.58, 0.91) 
IL-2 Pre-Acute 31 0.00 1  -  
0.0140 mRNA Acute 10 0.00 1.05 (0.46, 2.43) 
 Convalescent 16 0.01 2.85 (1.40, 5.81) 
IFN- Pre-Acute 36 0.62 1  -  
<0.0001 mRNA Acute 13 3.90 5.41 (3.04, 9.64) 










TNF Pre-Acute 37 3.29 1  -  
<0.0001 mRNA Acute 13 13.13 3.67 (2.18, 6.16) 
 Convalescent 16 6.36 1.86 (1.15, 3.02) 
IL-10 Pre-Acute 37 8.11 1  -  
0.0057 mRNA Acute 13 24.18 2.63 (1.41, 4.91) 










Table 3. Effect of the magnitude of cytokine production at the month indicated on the first 
raw (left-) on subsequent incidence of clinical malaria up to the follow up month indicated in 
the first row (-right). A) Heatmap of all cytokines and chemokines in supernatants. 
Statistically significant or trend differences indicating a reduction in the incidence of clinical 
malaria are marked in grey colors, and non-significant differences are in white. B) Incidence 
rate ratios (IRR) with 95% CI and p values for statistically significant or trend differences, for 
pro-inflammatory and regulatory cytokines and chemokines. 
A) 
  
Months 2.5-24 5.5-24 10.5-24 15-24 24-36 24-48 
TH1 cytokines 
IL-12 iRBC             
  uRBC             
IL-2 iRBC             
  uRBC             
IFN- iRBC             
  uRBC             
TH2 cytokines 
IL4 iRBC             
  uRBC             
IL5 iRBC             
  uRBC             
Pro-inflammatory 
cytokines 
IL-1 iRBC             
  uRBC             










  uRBC             
TNF iRBC             
  uRBC             
Pro-inflammatory 
chemokine 
IL-8 iRBC             
  uRBC             
Regulatory 
cytokine 
IL-10 iRBC             
  uRBC             
B) 
  Cytokines at 10.5 months 
on malaria risk up to       
24 months 
Cytokines at 24 months  
on malaria risk up to       
36 months 
Cytokines at 24 months on 
malaria risk up to             
48 months 
  IRR 95% CI p value IRR 95% CI p value IRR 95% CI p value 
IL-1 iRBC 0.93 0.85-1.01 0.078 0.69 0.48-0.99 0.030 0.72 0.51-1.02 0.077 
  uRBC 0.92 0.84-1.01 0.072 0.74 0.58-0.95 0.018 0.76 0.59-0.98 0.049 
IL-6 iRBC 0.93 0.84-1.03 0.152 0.73 0.54-1.00 0.034 0.77 0.56-1.04 0.112 
  uRBC 0.92 0.83-1.02 0.107 0.73 0.55-0.97 0.016 0.77 0.59-1.01 0.076 





  uRBC 0.89 0.80-0.99 0.037 0.6 0.41-0.88 0.006 0.62 0.43-0.89 0.022 
IL-10 iRBC 
 
  ns 0.82 0.67-1.00 0.044 0.85 0.72-1.00 0.089 
  uRBC 
 
  ns 0.79 0.66-0.94 0.005 0.77 0.66-0.90 0.002 














  uRBC 0.73 0.52-1.03 0.068 0.23 0.04-1.30 0.072 0.17 0.02-1.13 0.031 
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